SCFA production and their metabolic effects after inulin ingestio

Completed

Conditions: impaired fat metabolism
10013317
Overweight
10018424

Registration Number: NL-OMON38942

Lead Sponsor: niversiteit Maastricht

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Completed

Sex: Not specified

Target Recruitment: 15

Inclusion Criteria

Overweight/obese men (BMI>=25kg/m2<=35kg/m2)
- Aged 20 - 50 years
- Caucasian
- Normal fasting glucose (plasma glucose < 6.1 mmol/L)
- Normal blood pressure (systolic blood pressure 100-140mmHg, diastolic blood pressure 60-90 mmHg)
- Weight stable for at least 3 months (± 2kg)

Exclusion Criteria

- Type 2 diabetes mellitus (defined as FPG >= 7.0 mmol/l)
- Gastroenterological diseases or abdominal surgery
- Cardiovascular diseases, cancer, liver or kidney malfunction, disease with a life expectancy shorter then 5 years
- Abuse of products
- Plans to lose weight or following of a hypocaloric diet
- Regular supplementation of pre- or probiotic products, use of pre- or probiotics 3 months prior to the start of the study
- Intensive exercise training more than three hours a week
- Use of any medication that influences glucose or fat metabolism and inflammation (i.e. NSAIDs).
- Regular use of laxative products
- Use of antibiotics 3 months prior to the start of the study

Study & Design

Study Type: Interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Primary endpoint:<br /><br>Energy expenditure, fat and carbohydrate oxidation.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Secondary endpoints:<br /><br>- 13C incorporation in SCFA from labelled inulin in peripheral blood and faeces;<br /><br>- Plasma and fecal SCFA content after inulin ingestion;<br /><br>- Hormones that influence substrate and energy metabolism like Insulin,<br /><br>Glucagon, GLP-1, PYY, FIAF;<br /><br>- Circulating metabolites like Glucose, Free Fatty Acids, Triglycerides;<br /><br>- Inflammatory markers like TNF-a, IL-6, IL-1, Adipokines;<br /><br>- Indirect markers of insulin sensitivity like circulating insulin<br /><br>concentrations;<br /><br>- Breath sampling for 13CO2;<br /><br>- Adipose tissue and muscle gene/protein expression and inflammatory<br /><br>markers;<br /><br>- Appetite (VAS-scoring). </p><br>